Skip to main content

UBS Group AG

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1610520 ZURICH, V8

Position in ACAD

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$9,984,699
-$10,565,759 QoQ
Shares Held
448,549
-41.7% QoQ
Ownership
0.262%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 91.22169484270391.ToString("F0")% Shared 0.ToString("F0")% None 8.778305157296082.ToString("F0")%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Dec 31, 2021
CallValue
$0
CallShares
0
PutValue
$210,060
PutShares
9,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. ACAD ranks #106 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ACAD

Export CSV
30 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $9,984,699 448,549
2025-12-31 $20,550,458 769,392
2025-09-30 $14,187,812 664,846
2025-06-30 $15,880,329 736,223
2025-03-31 $17,554,278 1,056,850
2024-12-31 $22,777,395 1,241,275
2024-09-30 $9,291,856 604,152
2024-06-30 $7,402,703 455,551
2024-03-31 $6,358,359 343,881
2023-12-31 $9,623,409 307,359
2023-09-30 $3,015,464 144,696
2023-06-30 $3,345,838 139,701
2023-03-31 $2,883,053 153,191
2022-12-31 $5,847,717 367,319
2022-09-30 $835,553 51,073
2022-06-30 $476,269 33,802
2022-03-31 $1,536,346 63,433
2021-12-31 $210,060 9,000
2021-12-31 $5,109,311 218,908
2021-09-30 $3,612,724 217,503
2021-09-30 $149,490 9,000
2021-06-30 $219,510 9,000
2021-06-30 $289,143 11,855
2021-03-31 $694,923 26,935
2021-03-31 $232,200 9,000
2020-12-31 $2,066,817 38,661
2020-09-30 $1,253,092 30,378
2020-06-30 $1,183,976 24,427
2020-06-30 $1,415,324 29,200
2020-03-31 $1,014,211 24,005